Back in the early 1900s, before calculators lived in our pockets, crunching numbers was painstaking work. Adding machines existed, but they weren’t exactly convenient nor cheap. Enter Wilken Wilkenson ...

Kotak Institutional Equities has reiterated its ‘sell’ rating on Divi’s Laboratories with a price target of Rs 2600, saying growth rates could be lower in future, making current valuations look ...

Divi’s Laboratories Ltd, which has captured investor attention for some time now, has delivered healthy December quarter (Q3FY22) results. The company is into the custom synthesis (CS) business and ...

Drugmaker Divi's Laboratories is slated to release its April-June results on August 3. The low base of the last fiscal and strong sales in the custom synthesis segment are expected to drive profit and ...